Discover
TAK
Takeda Pharmaceutical Company Limited
15.95
16000 x undefined
12000 x undefined
bid
ask
-
0.08
0.50%
14000 @ 04:00 PM
16.14 +0.19 (1.19%)
| Ytd | 2.31% | |
| 1y | 3.77% |
15.90
day range
16.02
12.99
52 week range
18.90
| Open | 15.97 | Prev Close | 16.03 | Low | 15.90 | High | 16.02 | Mkt Cap | 50.40B |
| Vol | 2.03M | Avg Vol | 3.03M | EPS | -0.30 | P/E | N/A | Forward P/E | 30.11 |
| Beta | 0.09 | Short Ratio | 1.71 | Inst. Own | 3.14% | Dividend | 0.62 | Div Yield | 3.85 |
| Ex Div Date | 03-31 | Earning | 07-30 | 50-d Avg | 16.12 | 200-d Avg | 16.03 | 1yr Est | 20.49 |
| Income Statement | |||
| Total Revenue | 1.09T | ||
| Revenues (USD) | 6.85B | ||
| Cost of Revenue | 405.70B | ||
| Gross Profit | 688.84B | ||
| Operating Expenses | 1.11T | ||
| Research and Development Expense | 195.32B | ||
| Selling, General and Administrative Expense | 292.00B | ||
| Operating Income | -416.17B | ||
| Interest Expense | 43.65B | ||
| Income Tax Expense | -86.61B | ||
| Net Income | -368.67B | ||
| Net Income Common Stock | -368.67B | ||
| Net Income Common Stock (USD) | -2.31B | ||
| Consolidated Income | -368.61B | ||
| Net Income to Non-Controlling Interests | 62.00M | ||
| Earnings per Basic Share | -117.03 | ||
| Earnings per Basic Share (USD) | -0.73 | ||
| Earnings per Diluted Share | -115.94 | ||
| Earning Before Interest & Taxes (EBIT) | -411.64B | ||
| Earning Before Interest & Taxes (USD) | -2.58B | ||
| Weighted Average Shares | 1.58B | ||
| Balance Sheet | |||
| Cash and Equivalents | 595.05B | ||
| Cash and Equivalents (USD) | 3.73B | ||
| Investments | 490.63B | ||
| Investments Current | 41.89B | ||
| Investments Non-Current | 448.74B | ||
| Trade and Non-Trade Receivables | 844.31B | ||
| Current Assets | 3.09T | ||
| Property, Plant & Equipment Net | 2.12T | ||
| Total Assets | 15.51T | ||
| Debt Current | 653.38B | ||
| Total Debt | 5.59T | ||
| Current Liabilities | 2.83T | ||
| Debt Non-Current | 4.94T | ||
| Total Liabilities | 8.08T | ||
| Accumulated Retained Earnings (Deficit) | 712.38B | ||
| Accumulated Other Comprehensive Income | -2.85B | ||
| Shareholders Equity | 7.43T | ||
| Shareholders Equity (USD) | 46.52B | ||
| Assets Non-Current | 12.42T | ||
| Total Debt (USD) | 35.03B | ||
| Goodwill and Intangible Assets | 9.23T | ||
| Inventory | 1.40T | ||
| Liabilities Non-Current | 5.25T | ||
| Trade and Non-Trade Payables | 491.35B | ||
| Tax Assets | 578.30B | ||
| Tax Liabilities | 124.68B | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 163.87B | ||
| Net Cash Flow from Financing | -77.49B | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -60.98B | ||
| Capital Expenditure | -47.41B | ||
| Net Cash Flow - Business Acquisitions and Disposals | 515.00M | ||
| Issuance (Repayment) of Debt Securities | -25.61B | ||
| Payment of Dividends & Other Cash Distributions | -8.79B | ||
| Net Cash Flow from Investing | -58.02B | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 2.90B | ||
| Net Cash Flow from Operations | 74.53B | ||
| Effect of Exchange Rate Changes on Cash | 1.10B | ||
| Share Based Compensation | 19.71B | ||